Omalizumab-A review
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE). The US FDA has approved this molecule for chronic urticaria.
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
Wolters Kluwer Medknow Publications,
2015-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_abae883fd79949e08dadda6e4dbc0a08 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Kiran Godse |e author |
| 700 | 1 | 0 | |a Aayushi Mehta |e author |
| 700 | 1 | 0 | |a Sharmila Patil |e author |
| 700 | 1 | 0 | |a Manjyot Gautam |e author |
| 700 | 1 | 0 | |a Nitin Nadkarni |e author |
| 245 | 0 | 0 | |a Omalizumab-A review |
| 260 | |b Wolters Kluwer Medknow Publications, |c 2015-01-01T00:00:00Z. | ||
| 500 | |a 0019-5154 | ||
| 500 | |a 1998-3611 | ||
| 500 | |a 10.4103/0019-5154.160490 | ||
| 520 | |a Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE). The US FDA has approved this molecule for chronic urticaria. | ||
| 546 | |a EN | ||
| 690 | |a Anaphylaxis | ||
| 690 | |a atopic dermatitis | ||
| 690 | |a chronic urticaria | ||
| 690 | |a FDA approval | ||
| 690 | |a monoclonal antibody | ||
| 690 | |a Dermatology | ||
| 690 | |a RL1-803 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Indian Journal of Dermatology, Vol 60, Iss 4, Pp 381-384 (2015) | |
| 787 | 0 | |n http://www.e-ijd.org/article.asp?issn=0019-5154;year=2015;volume=60;issue=4;spage=381;epage=384;aulast=Godse | |
| 787 | 0 | |n https://doaj.org/toc/0019-5154 | |
| 787 | 0 | |n https://doaj.org/toc/1998-3611 | |
| 856 | 4 | 1 | |u https://doaj.org/article/abae883fd79949e08dadda6e4dbc0a08 |z Connect to this object online. |